Does Tirzepatide Reduce Visceral Fat? What the MRI and DXA Trial Data Show About Belly Fat

Most people starting tirzepatide watch the scale, but the number on the scale does not say where the lost weight came from. Visceral fat, the fat packed around the liver, intestines and other abdominal organs, matters more for metabolic health than the fat under the skin, and two tirzepatide substudies measured visceral fat directly with MRI and DXA scans.

This article covers what those scans showed, why clinicians pay so much attention to visceral fat, and how people on treatment can follow abdominal fat changes without a scanner. It is educational information rather than medical advice.

What is visceral fat and why does it matter?

Visceral fat is adipose tissue stored inside the abdominal cavity, around organs such as the liver, pancreas and intestines, rather than directly under the skin. Visceral fat matters because it is metabolically active, releasing free fatty acids and inflammatory signaling molecules that drain straight to the liver through the portal vein.

Higher visceral fat is associated with insulin resistance, fatty liver disease, higher triglycerides, lower HDL cholesterol, higher blood pressure and a greater risk of type 2 diabetes and cardiovascular disease. Two people with the same body mass index can carry very different amounts of visceral fat, which is one reason BMI alone is an incomplete measure of metabolic risk.

Does tirzepatide reduce visceral fat?

Tirzepatide reduced visceral fat substantially more than placebo or insulin in the clinical trials that measured abdominal fat directly. The two most informative datasets come from imaging substudies inside the SURMOUNT-1 and SURPASS-3 phase 3 trials.

What did the SURMOUNT-1 DXA substudy find?

The SURMOUNT-1 DXA substudy scanned 160 of the 2,539 SURMOUNT-1 participants, all adults with obesity or overweight without diabetes, at baseline and at week 72. People taking tirzepatide lost about 21.3 percent of body weight and about 40.1 percent of visceral fat mass, compared with 5.3 percent of body weight and 7.3 percent of visceral fat on placebo.

Is the weight lost on tirzepatide mostly fat?

Most of the weight lost on tirzepatide in SURMOUNT-1 was fat. In the DXA substudy, about 74 percent of the weight reduction came from fat mass and about 26 percent from lean mass, nearly the same split seen with placebo, even though people on tirzepatide lost about four times as much weight.

Lean mass on a DXA scan includes muscle along with water, organs and connective tissue, so a 10.9 percent lean mass reduction does not equal a 10.9 percent loss of muscle.

What did the SURPASS-3 MRI substudy find?

The SURPASS-3 MRI substudy followed 296 adults with type 2 diabetes who were randomly assigned to tirzepatide 5 mg, 10 mg or 15 mg, or to insulin degludec, and measured liver fat, visceral fat and abdominal subcutaneous fat by MRI over 52 weeks (Gastaldelli et al., Lancet Diabetes and Endocrinology 2022). Visceral fat volume fell in every tirzepatide group and rose on insulin degludec.

Abdominal subcutaneous fat followed the same pattern, falling by roughly 1.9 to 2.0 liters on tirzepatide and rising by about 1.1 liters on insulin degludec.

Does tirzepatide reduce liver fat too?

Tirzepatide reduced liver fat in the SURPASS-3 MRI substudy, with relative reductions of about 29.8 percent at 5 mg, 47.1 percent at 10 mg and 39.6 percent at 15 mg, compared with about 11.2 percent on insulin degludec. Average baseline liver fat was around 15 to 17 percent, well above the roughly 5 percent threshold commonly used to define fatty liver.

By week 52, between about 60 and 78 percent of people on tirzepatide had liver fat at or below 10 percent, compared with about 35 percent on insulin degludec. Liver fat and visceral fat tend to move together, because the liver receives much of what visceral fat releases.

Why does visceral fat seem to go first?

Visceral fat appears to respond earlier and more strongly to an energy deficit than subcutaneous fat does. Visceral fat cells are more responsive to the signals that trigger fat breakdown and less responsive to insulin's signal to store fat, so when calorie intake falls and insulin levels drop, the visceral compartment releases stored fat readily.

Studies of weight loss through diet or exercise show the same general pattern, in which a modest total weight loss can produce a proportionally larger visceral fat reduction. The tirzepatide effect is therefore probably driven mainly by the size of the energy deficit it helps people sustain, and whether GIP receptor activity has any additional direct effect on fat distribution remains an open research question.

How can people track visceral fat at home?

Waist circumference is the most practical home measure of visceral fat, because waist size tracks abdominal fat more closely than body weight or BMI and costs nothing to measure. A consistent method matters more than a perfect one, so the tape should go horizontally just above the top of the hip bones, first thing in the morning before eating, with the reading taken at the end of a normal exhale every two to four weeks.

Common risk thresholds are a waist above 40 inches (102 cm) for men and above 35 inches (88 cm) for women, with lower cutoffs often used for people of South Asian and East Asian descent. Waist to height ratio is another simple option, and a ratio above 0.5 is widely used as a marker of higher cardiometabolic risk.

In SURMOUNT-1, average waist circumference fell by roughly 14 to 18 cm across tirzepatide doses over 72 weeks, compared with about 4 cm on placebo, although results for individual participants varied widely.

Which methods measure visceral fat, and how accurate are they?

MRI and DXA with visceral fat software measure visceral fat directly, while tape measures and home scales estimate it. DXA body composition scans are offered by many sports medicine clinics and some imaging centers for a moderate out of pocket fee and use very low radiation, whereas MRI is the research standard and is rarely used for routine tracking.

What helps visceral fat loss alongside tirzepatide?

Several habits have evidence for reducing visceral fat and fit well with tirzepatide treatment.

Aerobic exercise. Pooled analyses of exercise trials suggest that regular aerobic activity reduces visceral fat even when body weight barely changes, and around 150 minutes per week of moderate activity is a common target.

Resistance training. Strength training two to three times per week helps preserve lean mass while fat is lost, which improves the overall quality of the weight that comes off.

Alcohol and sleep. Heavier drinking and short sleep are both associated with more abdominal fat, so limiting alcohol and aiming for seven or more hours of sleep supports the same goal.

Does visceral fat come back after stopping tirzepatide?

Visceral fat can return if weight is regained after stopping tirzepatide. In the SURMOUNT-4 trial, people who switched from tirzepatide to placebo after 36 weeks regained a substantial share of the lost weight over the following year, while those who continued treatment maintained or extended their loss (Aronne et al., JAMA 2024). A maintenance plan agreed with a clinician therefore matters as much as the initial loss.

The bottom line

Imaging substudies show that tirzepatide reduced visceral fat substantially, by about 40 percent on DXA over 72 weeks in SURMOUNT-1 and by about 1.2 to 1.9 liters on MRI over 52 weeks in SURPASS-3, alongside meaningful drops in liver fat. People considering tirzepatide should speak with a licensed clinician about whether treatment is appropriate for them.